These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 9548625)

  • 1. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
    Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
    Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 loss in gastric stromal tumors as a prognostic marker.
    Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A
    Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation.
    Yanagisawa N; Mikami T; Mitomi H; Saegusa M; Koike M; Okayasu I
    Cancer; 2001 Jan; 91(2):408-16. PubMed ID: 11180088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.
    Aaltomaa S; Lipponen P; Viitanen J; Kankkunen JP; Ala-Opas M; Kosma VM
    Eur Urol; 2000 Nov; 38(5):555-62. PubMed ID: 11096236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.
    Aaltomaa S; Lipponen P; Ala-Opas M; Kosma VM
    Eur Urol; 2001 Feb; 39(2):138-44. PubMed ID: 11223672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
    Poncelet C; Walker F; Madelenat P; Bringuier AF; Scoazec JY; Feldmann G; Darai E
    Hum Pathol; 2001 Nov; 32(11):1190-6. PubMed ID: 11727257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of CD44 isoform expression in endometrial cancer.
    Tempfer C; Haeusler G; Kaider A; Hefler L; Hanzal E; Reinthaller A; Breitenecker G; Kainz C
    Br J Cancer; 1998 Apr; 77(7):1137-9. PubMed ID: 9569051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas.
    Tran TA; Kallakury BV; Sheehan CE; Ross JS
    Hum Pathol; 1997 Jul; 28(7):809-14. PubMed ID: 9224749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of CD44 variants expression in colorectal cancer.
    Li XD; Ji M; Wu J; Jiang JT; Wu CP
    Tumori; 2013; 99(1):88-92. PubMed ID: 23549006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
    Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
    Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
    Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
    J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
    Liu YJ; Yan PS; Li J; Jia JF
    World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer.
    Tempfer C; Sliutz G; Haeusler G; Speiser P; Reinthaller A; Breitenecker G; Vavra N; Kainz C
    Br J Cancer; 1998 Oct; 78(8):1091-4. PubMed ID: 9792156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44V6 expression in human colorectal carcinoma.
    Coppola D; Hyacinthe M; Fu L; Cantor AB; Karl R; Marcet J; Cooper DL; Nicosia SV; Cooper HS
    Hum Pathol; 1998 Jun; 29(6):627-35. PubMed ID: 9635685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer.
    Wu XJ; Li XD; Zhang H; Zhang X; Ning ZH; Yin YM; Tian Y
    J Int Med Res; 2015 Apr; 43(2):173-9. PubMed ID: 25571897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
    Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
    J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer.
    Bendardaf R; Elzagheid A; Lamlum H; Ristamäki R; Collan Y; Pyrhönen S
    Oncol Rep; 2005 May; 13(5):831-5. PubMed ID: 15809746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
    Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
    Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids.
    Afify A; Pang L; Howell L
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):446-50. PubMed ID: 18091389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence.
    Gilcrease MZ; Guzman-Paz M; Niehans G; Cherwitz D; McCarthy JB; Albores-Saavedra J
    Cancer; 1999 Dec; 86(11):2320-6. PubMed ID: 10590373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.